Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Linda Cingolani"'
Autor:
Linda Cingolani, Brigida Barberio, Fabiana Zingone, Antonio Ferronato, Lorenzo Bertani, Francesco Costa, Giorgia Bodini, Maria Giulia Demarzo, Piera Melatti, Alessandro Gubbiotti, Davide Massimi, Cesare Casadei, Renata D’Incà, Edoardo Vincenzo Savarino
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Abstract To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induce
Externí odkaz:
https://doaj.org/article/e1df2d0bb34a4efe88e26cf19e6d58b1
Autor:
Brigida Barberio, Linda Cingolani, Cristina Canova, Giulia Barbieri, Renato Sablich, Maria Teresa Urbano, Lorenzo Bertani, Francesco Costa, Giorgia Bodini, Maria Giulia Demarzo, Antonio Ferronato, Andrea Buda, Piera Melatti, Davide Massimi, Edoardo Vincenzo Savarino, Fabiana Zingone
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Adalimumab is an effective and safe biological drug for the treatment of inflammatory bowel disease (IBD). Nowadays, several biosimilar agents are available, but data regarding their efficacy and safety in patients with IBD are still lack
Externí odkaz:
https://doaj.org/article/894dccb3e3904386a4d6bb5291f7f2fc
Autor:
Davide Massimi, Brigida Barberio, Lorenzo Bertani, Francesco Costa, Antonio Ferronato, Sonia Facchin, Romilda Cardin, Linda Cingolani, Cesare Casadei, Renata D’Incà, Fabiana Zingone, Edoardo Vincenzo Savarino
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Current literature still lacks studies evaluating the effectiveness and safety of switching from Infliximab originator to SB2 biosimilar in Inflammatory Bowel Diseases (IBDs). We aimed to verify the ability of SB2 to maintain the clinical
Externí odkaz:
https://doaj.org/article/2597c903fe2c465ea68be45f74e33152
Autor:
Cesare Casadei, Antonio Ferronato, Fabiana Zingone, Brigida Barberio, Davide Massimi, Sonia Facchin, Linda Cingolani, Lorenzo Bertani, Renata D'Incà, Edoardo Savarino, Romilda Cardin, Francesco Costa
Publikováno v:
Therapeutic Advances in Gastroenterology
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Therapeutic Advances in Gastroenterology, Vol 14 (2021)
Background: Current literature still lacks studies evaluating the effectiveness and safety of switching from Infliximab originator to SB2 biosimilar in Inflammatory Bowel Diseases (IBDs). We aimed to verify the ability of SB2 to maintain the clinical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cb289286fa8687b77498cf580346cf4
http://hdl.handle.net/11577/3401603
http://hdl.handle.net/11577/3401603
Autor:
Maria Giulia Demarzo, Antonio Ferronato, Piera Melatti, Brigida Barberio, Lorenzo Bertani, Francesco Costa, Edoardo Savarino, A. Gubbiotti, Fabiana Zingone, Linda Cingolani, Renata D'Incà, Cesare Casadei, Davide Massimi, Giorgia Bodini
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
Scientific Reports
Scientific Reports
To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induced by the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd1d480555950479581b5e09cd67ef8
http://hdl.handle.net/11577/3394280
http://hdl.handle.net/11577/3394280
Autor:
Fabiana Zingone, Monica Siniscalchi, Edoardo Vincenzo Savarino, Brigida Barberio, Linda Cingolani, Renata D'Incà, Francesca Romana De Filippo, Silvia Camera, Carolina Ciacci
BACKGROUND After the COVID-19 outbreak, the Italian Government stopped most regular health care activity. As a result, patients with inflammatory bowel disease (IBD) had limited access to outpatient clinics and hospitals. OBJECTIVE This study aimed t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19fa8913f8c4d5f11ea21346a814febb
https://doi.org/10.2196/preprints.19574
https://doi.org/10.2196/preprints.19574
Autor:
Ilaria Marsilio, Greta Lorenzon, Renata D'Incà, Edoardo Savarino, Linda Cingolani, D. Maniero, Fabiana Zingone, Brigida Barberio, Anna D'Odorico
Publikováno v:
Nutrients
Nutrients, Vol 12, Iss 1110, p 1110 (2020)
Volume 12
Issue 4
Nutrients, Vol 12, Iss 1110, p 1110 (2020)
Volume 12
Issue 4
Background and aim: Nutritional deficiencies are frequent in coeliac disease (CeD), mostly because of the nutritional deficits in gluten-free foods and because of wrong behaviors. We aimed to investigate the level of nutritional knowledge in a cohort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c47585a36d0001eef03815ea81bec3a
https://pubmed.ncbi.nlm.nih.gov/32316215
https://pubmed.ncbi.nlm.nih.gov/32316215
Autor:
Edoardo Savarino, Monica Siniscalchi, Renata D'Incà, Francesca Romana De Filippo, S. Camera, Linda Cingolani, Carolina Ciacci, Fabiana Zingone, Brigida Barberio
Publikováno v:
Journal of Medical Internet Research
Journal of Medical Internet Research, Vol 22, Iss 11, p e19574 (2020)
Journal of Medical Internet Research, Vol 22, Iss 11, p e19574 (2020)
Background After the COVID-19 outbreak, the Italian Government stopped most regular health care activity. As a result, patients with inflammatory bowel disease (IBD) had limited access to outpatient clinics and hospitals. Objective This study aimed t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c671660c221541081cf8ca85aa507ac3
http://hdl.handle.net/11577/3362935
http://hdl.handle.net/11577/3362935
Autor:
Maria Chiara Maccarone, Linda Cingolani, Brigida Barberio, Carla Marinelli, A. Gubbiotti, Fabiana Zingone, Matteo Ghisa, Edoardo Savarino, Greta Lorenzon, Renata D'Incà
Publikováno v:
Journal of Crohn's and Colitis. 14:S548-S549
Background Currently, ulcerative colitis (UC) can be treated with different anti-Tumor Necrosis Factor (TNF) drugs, which selection is mainly based on physician’s perspective. Indeed, head-to-head comparison studies evaluating the effectiveness and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfdf4ccf1b137d64a723eb875946d944
https://doi.org/10.1093/ecco-jcc/jjz203.796
https://doi.org/10.1093/ecco-jcc/jjz203.796
Autor:
Linda Cingolani, Brigida Barberio, A. Gubbiotti, Fabiana Zingone, Cesare Casadei, Davide Massimi, A Ferronato, Andrea Buda, Edoardo Savarino, Piera Melatti
Publikováno v:
Journal of Crohn's and Colitis. 14:S397-S397
Background Recently, various adalimumab (ADA) biosimilars have been approved by the EMA with the same indications of the reference product (Humira), despite the lack of data in terms of efficacy and safety in patients with inflammatory bowel disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::657d8d4dbc795491086cd1abaa8e5994
https://doi.org/10.1093/ecco-jcc/jjz203.567
https://doi.org/10.1093/ecco-jcc/jjz203.567